BioCentury
ARTICLE | Clinical News

Gilead begins Phase III Viread trial

August 11, 2003 7:00 AM UTC

GILD began an open-label, international Phase III trial (Study 934) in 300 treatment-nave patients comparing a once-daily regimen of Viread tenofovir and Emtriva emtricitabine plus Sustiva efavirenz to a regimen of twice-daily Combivir lamivudine/zidovudine plus once-daily Sustiva. Viread and Emtriva are both from GILD. GlaxoSmithKline (LSE:GSK; GSK) markets Combivir, and Bristol-Myers (BMY) markets Sustiva. Viread and Emtriva are both approved in the U.S. to treat HIV infection in combination with other antiretrovirals. ...